

# John R Kirwan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5562431/publications.pdf>

Version: 2024-02-01

83  
papers

5,272  
citations

109264

35  
h-index

82499

72  
g-index

89  
all docs

89  
docs citations

89  
times ranked

5243  
citing authors

#	ARTICLE	IF	CITATIONS
1	Developing a group intervention to manage fatigue in rheumatoid arthritis through modifying physical activity. <i>BMC Musculoskeletal Disorders</i> , 2019, 20, 194.	0.8	12
2	Reducing arthritis fatigue impact: two-year randomised controlled trial of cognitive behavioural approaches by rheumatology teams (RAFT). <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 465-472.	0.5	48
3	Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations. <i>Health Technology Assessment</i> , 2019, 23, 1-130.	1.3	18
4	“Everyone assumes a man to be quite strong”: Men, masculinity and rheumatoid arthritis: A case study approach. <i>Sociology of Health and Illness</i> , 2018, 40, 115-129.	1.1	21
5	Coping Strategies, Psychological Impact, and Support Preferences of Men With Rheumatoid Arthritis: A Multicenter Survey. <i>Arthritis Care and Research</i> , 2018, 70, 851-860.	1.5	14
6	Achieving consensus on minimum data items (including core outcome domains) for a longitudinal observational cohort study in rheumatoid arthritis. <i>Rheumatology</i> , 2017, 56, kew416.	0.9	3
7	“You Obviously Just Have to Put on a Brave Face”: A Qualitative Study of the Experiences and Coping Styles of Men With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2017, 69, 330-337.	1.5	23
8	Physical activity interventions for fatigue in rheumatoid arthritis: a systematic review. <i>Physical Therapy Reviews</i> , 2017, 22, 12-22.	0.3	9
9	Emerging Guidelines for Patient Engagement in Research. <i>Value in Health</i> , 2017, 20, 481-486.	0.1	144
10	Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. <i>Rheumatology</i> , 2017, 56, 1573-1578.	0.9	71
11	Stiffness Is the Cardinal Symptom of Inflammatory Musculoskeletal Diseases, Yet Still Variably Measured: Report from the OMERACT 2016 Stiffness Special Interest Group. <i>Journal of Rheumatology</i> , 2017, 44, 1904-1910.	1.0	11
12	Successful Stepwise Development of Patient Research Partnership: 14 Years’ Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT). <i>Patient</i> , 2017, 10, 141-152.	1.1	41
13	Development and validation of novel biomarker assays for osteoarthritis. <i>PLoS ONE</i> , 2017, 12, e0181334.	1.1	5
14	Biologic interventions for fatigue in rheumatoid arthritis. <i>The Cochrane Library</i> , 2016, 2016, CD008334.	1.5	60
15	Identifying different typologies of experiences and coping strategies in men with rheumatoid arthritis: a Q-methodology study. <i>BMJ Open</i> , 2016, 6, e012051.	0.8	8
16	Translating patient reported outcome measures: methodological issues explored using cognitive interviewing with three rheumatoid arthritis measures in six European languages. <i>Rheumatology</i> , 2016, 55, 1009-1016.	0.9	13
17	Men, rheumatoid arthritis, psychosocial impact and self-management: A narrative review. <i>Journal of Health Psychology</i> , 2016, 21, 2168-2182.	1.3	23
18	Remission in Rheumatoid Arthritis: Working Toward Incorporation of the Patient Perspective at OMERACT 12. <i>Journal of Rheumatology</i> , 2016, 43, 203-207.	1.0	20

#	ARTICLE	IF	CITATIONS
19	Item Development and Face Validity of the Rheumatoid Arthritis Patient Priorities in Pharmacological Interventions Outcome Measures. <i>Patient</i> , 2016, 9, 103-115.	1.1	0
20	Recommendations for the Involvement of Patient Research Partners (PRP) in OMERACT Working Groups. A Report from the OMERACT 2014 Working Group on PRP. <i>Journal of Rheumatology</i> , 2016, 43, 187-193.	1.0	46
21	Rheumatoid arthritis: previously untreated early disease. <i>Clinical Evidence</i> , 2016, 2016, .	0.2	4
22	The patient perspective on remission in rheumatoid arthritis: "You've got limits, but you're back to being you again"™. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1004-1010.	0.5	71
23	Outcome Measures in Polymyalgia Rheumatica. A Systematic Review. <i>Journal of Rheumatology</i> , 2015, 42, 2503-2511.	1.0	14
24	Stiffness is more than just duration and severity: a qualitative exploration in people with rheumatoid arthritis. <i>Rheumatology</i> , 2015, 54, 615-622.	0.9	35
25	The Spirit of OMERACT: Q Methodology Analysis of Conference Characteristics Valued by Delegates. <i>Journal of Rheumatology</i> , 2015, 42, 1982-1992.	1.0	5
26	"An Impediment to Living Life": Why and How Should We Measure Stiffness in Polymyalgia Rheumatica?. <i>PLoS ONE</i> , 2015, 10, e0126758.	1.1	23
27	The intelligent use of systemic glucocorticoids in rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 143-157.	1.3	3
28	Updating the OMERACT Filter at OMERACT 11. <i>Journal of Rheumatology</i> , 2014, 41, 975-977.	1.0	19
29	Updating the OMERACT Filter: Implications for Patient-reported Outcomes. <i>Journal of Rheumatology</i> , 2014, 41, 1011-1015.	1.0	54
30	Updating the OMERACT Filter: Core Areas as a Basis for Defining Core Outcome Sets. <i>Journal of Rheumatology</i> , 2014, 41, 994-999.	1.0	20
31	Biological treatment in rheumatoid arthritis: when to stop?. <i>Lancet</i> , The, 2014, 383, 288-289.	6.3	7
32	Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 745-753.	2.4	625
33	Reliability and sensitivity to change of the Bristol Rheumatoid Arthritis Fatigue scales. <i>Rheumatology</i> , 2013, 52, 1832-1839.	0.9	39
34	Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 204-210.	0.5	160
35	Non-pharmacological interventions for fatigue in rheumatoid arthritis. <i>The Cochrane Library</i> , 2013, , CD008322.	1.5	134
36	Efficacy, safety and mechanism of action of modified-release prednisone in rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2012, 4, 159-166.	1.2	8

#	ARTICLE	IF	CITATIONS
37	Symptom control with low-dose glucocorticoid therapy for rheumatoid arthritis. <i>Rheumatology</i> , 2012, 51, iv14-iv20.	0.9	10
38	Combination Therapy Including Glucocorticoids: The New Gold Standard for Early Treatment in Rheumatoid Arthritis?. <i>Annals of Internal Medicine</i> , 2012, 156, 390.	2.0	9
39	Alleviation of morning joint stiffness by low-dose prednisone in rheumatoid arthritis is associated with circadian changes in IL-6 and cortisol. <i>International Journal of Clinical Rheumatology</i> , 2011, 6, 241-249.	0.3	26
40	The Impact Triad (Severity, Importance, Self-management) as a Method of Enhancing Measurement of Personal Life Impact of Rheumatic Diseases. <i>Journal of Rheumatology</i> , 2011, 38, 191-194.	1.0	39
41	Patient Perspective: Choosing or Developing Instruments. <i>Journal of Rheumatology</i> , 2011, 38, 1716-1719.	1.0	23
42	Fatigue in rheumatoid arthritis: time for a conceptual model. <i>Rheumatology</i> , 2011, 50, 1004-1006.	0.9	163
43	Collaboration with patients in the design of patient-reported outcome measures: Capturing the experience of fatigue in rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2010, 62, 1552-1558.	1.5	90
44	Measuring fatigue in rheumatoid arthritis: A cross-sectional study to evaluate the Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional questionnaire, visual analog scales, and numerical rating scales. <i>Arthritis Care and Research</i> , 2010, 62, 1559-1568.	1.5	140
45	Effect of novel therapeutic glucocorticoids on circadian rhythms of hormones and cytokines in rheumatoid arthritis. <i>Annals of the New York Academy of Sciences</i> , 2010, 1193, 127-133.	1.8	38
46	Low-dose glucocorticoid therapy in rheumatoid arthritis: an obligatory therapy. <i>Annals of the New York Academy of Sciences</i> , 2010, 1193, 123-126.	1.8	26
47	Revitalising glucocorticoids for (rheumatoid) arthritis. <i>Clinical Medicine</i> , 2010, 10, 159-160.	0.8	0
48	Patient Perspective on Outcomes in Rheumatology – A Position Paper for OMERACT 9. <i>Journal of Rheumatology</i> , 2009, 36, 2067-2070.	1.0	38
49	Progress on Incorporating the Patient Perspective in Outcome Assessment in Rheumatology and the Emergence of Life Impact Measures at OMERACT 9. <i>Journal of Rheumatology</i> , 2009, 36, 2071-2076.	1.0	36
50	The use of glucocorticoids in preventing joint destruction: Comment on the review by Schett et al. <i>Arthritis and Rheumatism</i> , 2009, 60, 1202-1203.	6.7	0
51	Sensitivity to change of the Rheumatoid Arthritis Self-Efficacy scale (RASE) and predictors of change in self-efficacy. <i>Musculoskeletal Care</i> , 2008, 6, 49-67.	0.6	23
52	Glucocorticoids: action and new therapeutic insights in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2007, 19, 233-237.	2.0	54
53	Effects of glucocorticoids on radiological progression in rheumatoid arthritis. <i>The Cochrane Library</i> , 2007, , CD006356.	1.5	201
54	The effect of therapeutic glucocorticoids on the adrenal response in a randomized controlled trial in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 1415-1421.	6.7	40

#	ARTICLE	IF	CITATIONS
55	The benefit of low-dose glucocorticoid treatment in early rheumatoid arthritis may outweigh the risk: Comment on the editorial by Harris. <i>Arthritis and Rheumatism</i> , 2006, 54, 2031-2032.	6.7	4
56	Patients and professionals as research partners: Challenges, practicalities, and benefits. <i>Arthritis and Rheumatism</i> , 2006, 55, 676-680.	6.7	214
57	Measuring sensation in the feet of patients with rheumatoid arthritis. <i>Musculoskeletal Care</i> , 2006, 4, 12-23.	0.6	21
58	Early rheumatoid arthritis: combination therapy with disease-modifying antirheumatic drugs and low-dose glucocorticoids?. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 182-183.	3.2	1
59	Clinical and psychological outcomes of patient education in rheumatoid arthritis. <i>Musculoskeletal Care</i> , 2005, 3, 1-16.	0.6	27
60	Outcomes generated by patients with rheumatoid arthritis: how important are they?. <i>Musculoskeletal Care</i> , 2005, 3, 131-142.	0.6	98
61	Reduced Loss of Hand Bone Density With Prednisolone in Early Rheumatoid Arthritis. <i>Archives of Internal Medicine</i> , 2005, 165, 1293.	4.3	103
62	Systemic glucocorticoids in rheumatoid arthritis. , 2005, , 247-264.		0
63	Progress since OMERACT 6 on including patient perspective in rheumatoid arthritis outcome assessment. <i>Journal of Rheumatology</i> , 2005, 32, 2246-9.	1.0	28
64	Incorporating the patient perspective into outcome assessment in rheumatoid arthritis--progress at OMERACT 7. <i>Journal of Rheumatology</i> , 2005, 32, 2250-6.	1.0	152
65	Systematic review of rheumatoid arthritis patient education. <i>Arthritis and Rheumatism</i> , 2004, 51, 1045-1059.	6.7	120
66	New modes of practice. <i>Current Opinion in Rheumatology</i> , 2004, 16, 125-129.	2.0	5
67	Patient education for adults with rheumatoid arthritis. <i>The Cochrane Library</i> , 2003, , .	1.5	131
68	Outcomes from the Patient Perspective Workshop at OMERACT 6. <i>Journal of Rheumatology</i> , 2003, 30, 868-72.	1.0	129
69	Patient education programmes for adults with rheumatoid arthritis. <i>BMJ: British Medical Journal</i> , 2002, 325, 558-559.	2.4	47
70	SYSTEMIC LOW-DOSE GLUCOCORTICOID TREATMENT IN RHEUMATOID ARTHRITIS. <i>Rheumatic Disease Clinics of North America</i> , 2001, 27, 389-403.	0.8	19
71	Systemic glucocorticoids in chronic arthritis. , 2001, , 175-190.		0
72	Does treatment with glucocorticoids or with disease-modifying antirheumatic drugs reduce the rate of radiographic progression in rheumatoid arthritis? Comment on the article by Abu-Shakra et al. <i>Arthritis and Rheumatism</i> , 1999, 42, 1066-1066.	6.7	0

#	ARTICLE	IF	CITATIONS
73	The analysis of a bivariate multi-state Markov transition model for rheumatoid arthritis with an incomplete disease history. , 1999, 18, 1677-1690.		5
74	The Use of Guidelines for Managing and Treating Osteoarthritis. Disease Management and Health Outcomes, 1998, 3, 131-142.	0.3	1
75	Low Dose Corticosteroids in Early Rheumatoid Arthritis. Drugs and Aging, 1996, 8, 157-161.	1.3	5
76	The Effect of Glucocorticoids on Joint Destruction in Rheumatoid Arthritis. New England Journal of Medicine, 1995, 333, 142-147.	13.9	774
77	Patient education in rheumatoid arthritis. Current Opinion in Rheumatology, 1990, 2, 336-339.	2.0	16
78	The risks of local and systemic corticosteroid administration. Bailliere's Clinical Rheumatology, 1990, 4, 305-332.	1.0	27
79	Corticosteroid therapy in rheumatoid arthritis. Bailliere's Clinical Rheumatology, 1990, 4, 621-647.	1.0	11
80	THE POTENTIAL OF COMPUTER APPLICATIONS IN RHEUMATOLOGY. Rheumatology, 1987, 26, 3-4.	0.9	2
81	Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute-phase response. Arthritis and Rheumatism, 1987, 30, 618-623.	6.7	168
82	Reporting of Significance Levels Versus Pearson's Correlation Coefficient. Rheumatology, 1984, 23, 232-233.	0.9	9
83	Rheumatoid Arthritis: Disease-modifying Antirheumatic Drugs. Clinics in Rheumatic Diseases, 1983, 9, 581-599.	1.2	43